MAGEA3 and melanoma: TCR repertoire diversity may also be affected by the vaccine formulation as reported by Connerotte et al. who described that only the vaccine formulation including MAGE-3-peptide-pulsed dendritic cells was able to generate a polyclonal T-cell response in melanoma patients with tumor regression, whereas MAGE-3 peptide or ALVAC mini-MAGE1/3 vaccinations induced a monoclonal T-cell response [77].